Desonide
(Synonyms: 地索奈德) 目录号 : GC15690
A nonfluorinated synthetic corticosteroid
Cas No.:638-94-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Desonide is a nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.Target: Glucocorticoid ReceptorDesonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses [1]. Desonide induced significant colorimetric improvement compared with placebo. A good to excellent response was achieved in 30% for desonide, and 6% for placebo. Decreased pigmentation in the desonide-treated axillae was associated with recovery of disruption at the basal membrane. Desonide showed depigmenting properties in women with axillary hyperpigmentation [2]. Given the favorable safety profile of all other desonide preparations and their utility as a low potency corticosteroid, desonide foam promises to be a useful addition to the armamentarium, when other desonide vehicles might be less acceptable [3].
References:
[1]. Kahanek, N., C. Gelbard, and A. Hebert, Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs, 2008. 17(7): p. 1097-104.
[2]. Castanedo-Cazares, J.P., et al., Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol, 2013. 6: p. 29-36.
[3]. Parish, D. and N. Scheinfeld, Desonide foam: a review. Drugs Today (Barc), 2008. 44(1): p. 55-62.
| Cas No. | 638-94-8 | SDF | |
| 别名 | 地索奈德 | ||
| 化学名 | (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one | ||
| Canonical SMILES | O=C(C([H])([H])O[H])[C@@]12OC(C([H])([H])[H])(C([H])([H])[H])O[C@]1([H])C([H])([H])[C@]([C@@](C([H])([H])C3([H])[H])([H])[C@@]4([H])[C@@](C([H])([H])[H])(C([H])=C5[H])C3=C([H])C5=O)([H])[C@]2(C([H])([H])[H])C([H])([H])[C@]4([H])O[H] | ||
| 分子式 | C24H32O6 | 分子量 | 416.51 |
| 溶解度 | ≥ 20.85mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4009 mL | 12.0045 mL | 24.009 mL |
| 5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。